Abstract
Objective: Gastric neuroendocrine carcinomas (NEC) and mixed adenoneuroendocrine carcinoma (MANEC) are very rare, aggressive tumors of the stomach. We aimed to examine predictive role of pretreatment 18 F-FDG PET/CT-assessed metabolic parameter of primary tumors and metastases in patients with gastric NEC and MANEC. Methods: We conducted a review of the 27 patients with histopathologically confirmed NECs (n = 10) and MANEC (n = 17) of the stomach at our institution between January 2005 and December 2012. All patients underwent 18 F-FDG-PET examination at diagnosis. Metabolic parameters [SUV max , SUV mean , metabolic tumor volume (MTV) and total lesion glycolysis (TLG)] of the primary tumor and metastases on baseline PET/CT were analyzed. Results: The median follow-up duration was 39.4 months (95 % CI 20.0–58.1 months) and the median overall survival (OS) was 25.7 months (95 % CI 14.1–37.2 months). All gastric lesions were well visualized (average SUV max = 12.0, range 3.0–41.8). When subjects were divided into two groups by ROC cut-off value of 210.9 and 612, patients with high TLG in primary lesion and metastases showed poorer prognosis compared to low TLG patients (P = 0.09, P = 0.002, respectively). In the sub-analysis of patients with metastasis (n = 12), patients with high TLG in whole body tumor showed significantly shorter OS compared to those with low TLG (31.7 ± 11.4 vs. 7.2 ± 2.1 months, P = 0.006). Conclusion: 18 F-FDG PET/CT is useful in evaluating prognosis of advanced gastric cancer with neuroendocrine carcinoma components. Baseline MTV of primary gastric cancer with metastatic disease, and MTV, TLG of metastases may be prognostic markers in patients with gastric NEC and MANEC.
| Original language | English |
|---|---|
| Pages (from-to) | 279-286 |
| Number of pages | 8 |
| Journal | Annals of Nuclear Medicine |
| Volume | 30 |
| Issue number | 4 |
| DOIs | |
| Publication status | Published - 2016 May 1 |
Fingerprint
All Science Journal Classification (ASJC) codes
- Radiology Nuclear Medicine and imaging
Cite this
}
Prognostic value of 18 F-fluorodeoxyglucose positron emission tomography in patients with gastric neuroendocrine carcinoma and mixed adenoneuroendocrine carcinoma . / Lim, Sun Min; Kim, Hyunki; Kang, Beodeul; Kim, Hyo Song; Rha, SunYoung; Noh, Sung Hoon; Hyung, WooJin; Cheong, Jae Ho; Kim, Hyoung Il; Chung, Hyuncheol; Yun, Mijin; Cho, Arthur; Jung, Minkyu.
In: Annals of Nuclear Medicine, Vol. 30, No. 4, 01.05.2016, p. 279-286.Research output: Contribution to journal › Article
TY - JOUR
T1 - Prognostic value of 18 F-fluorodeoxyglucose positron emission tomography in patients with gastric neuroendocrine carcinoma and mixed adenoneuroendocrine carcinoma
AU - Lim, Sun Min
AU - Kim, Hyunki
AU - Kang, Beodeul
AU - Kim, Hyo Song
AU - Rha, SunYoung
AU - Noh, Sung Hoon
AU - Hyung, WooJin
AU - Cheong, Jae Ho
AU - Kim, Hyoung Il
AU - Chung, Hyuncheol
AU - Yun, Mijin
AU - Cho, Arthur
AU - Jung, Minkyu
PY - 2016/5/1
Y1 - 2016/5/1
N2 - Objective: Gastric neuroendocrine carcinomas (NEC) and mixed adenoneuroendocrine carcinoma (MANEC) are very rare, aggressive tumors of the stomach. We aimed to examine predictive role of pretreatment 18 F-FDG PET/CT-assessed metabolic parameter of primary tumors and metastases in patients with gastric NEC and MANEC. Methods: We conducted a review of the 27 patients with histopathologically confirmed NECs (n = 10) and MANEC (n = 17) of the stomach at our institution between January 2005 and December 2012. All patients underwent 18 F-FDG-PET examination at diagnosis. Metabolic parameters [SUV max , SUV mean , metabolic tumor volume (MTV) and total lesion glycolysis (TLG)] of the primary tumor and metastases on baseline PET/CT were analyzed. Results: The median follow-up duration was 39.4 months (95 % CI 20.0–58.1 months) and the median overall survival (OS) was 25.7 months (95 % CI 14.1–37.2 months). All gastric lesions were well visualized (average SUV max = 12.0, range 3.0–41.8). When subjects were divided into two groups by ROC cut-off value of 210.9 and 612, patients with high TLG in primary lesion and metastases showed poorer prognosis compared to low TLG patients (P = 0.09, P = 0.002, respectively). In the sub-analysis of patients with metastasis (n = 12), patients with high TLG in whole body tumor showed significantly shorter OS compared to those with low TLG (31.7 ± 11.4 vs. 7.2 ± 2.1 months, P = 0.006). Conclusion: 18 F-FDG PET/CT is useful in evaluating prognosis of advanced gastric cancer with neuroendocrine carcinoma components. Baseline MTV of primary gastric cancer with metastatic disease, and MTV, TLG of metastases may be prognostic markers in patients with gastric NEC and MANEC.
AB - Objective: Gastric neuroendocrine carcinomas (NEC) and mixed adenoneuroendocrine carcinoma (MANEC) are very rare, aggressive tumors of the stomach. We aimed to examine predictive role of pretreatment 18 F-FDG PET/CT-assessed metabolic parameter of primary tumors and metastases in patients with gastric NEC and MANEC. Methods: We conducted a review of the 27 patients with histopathologically confirmed NECs (n = 10) and MANEC (n = 17) of the stomach at our institution between January 2005 and December 2012. All patients underwent 18 F-FDG-PET examination at diagnosis. Metabolic parameters [SUV max , SUV mean , metabolic tumor volume (MTV) and total lesion glycolysis (TLG)] of the primary tumor and metastases on baseline PET/CT were analyzed. Results: The median follow-up duration was 39.4 months (95 % CI 20.0–58.1 months) and the median overall survival (OS) was 25.7 months (95 % CI 14.1–37.2 months). All gastric lesions were well visualized (average SUV max = 12.0, range 3.0–41.8). When subjects were divided into two groups by ROC cut-off value of 210.9 and 612, patients with high TLG in primary lesion and metastases showed poorer prognosis compared to low TLG patients (P = 0.09, P = 0.002, respectively). In the sub-analysis of patients with metastasis (n = 12), patients with high TLG in whole body tumor showed significantly shorter OS compared to those with low TLG (31.7 ± 11.4 vs. 7.2 ± 2.1 months, P = 0.006). Conclusion: 18 F-FDG PET/CT is useful in evaluating prognosis of advanced gastric cancer with neuroendocrine carcinoma components. Baseline MTV of primary gastric cancer with metastatic disease, and MTV, TLG of metastases may be prognostic markers in patients with gastric NEC and MANEC.
UR - http://www.scopus.com/inward/record.url?scp=84964291949&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84964291949&partnerID=8YFLogxK
U2 - 10.1007/s12149-016-1059-x
DO - 10.1007/s12149-016-1059-x
M3 - Article
VL - 30
SP - 279
EP - 286
JO - Annals of Nuclear Medicine
JF - Annals of Nuclear Medicine
SN - 0914-7187
IS - 4
ER -